Satheesh Chonat MD

Pediatric Hematology & Oncology•Atlanta, GA

Associate Professor, Department of Pediatrics, Emory University and Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta

Join to View Full Profile

1405 Clifton Rd NEAtlanta, GA 30322
Phone+1 404-785-1112
Fax+1 404-785-6288

Education & Training

Cincinnati Children's Hospital Medical CenterFellowship, Pediatric Hematology/Oncology, 2012 - 2015
University of Michigan Health - Sparrow/Michigan State UniversityResidency, Pediatrics, 2009 - 2012
Cambridge University Hospitals and London School of PaediatricsSpeciality Training Registrar, General Pediatrics, Neonatology and Hematology/Oncology, 2003 - 2009
M.S. Ramaiah Medical CollegeClass of 2003

Certifications & Licensure

GA State Medical License 2015 - 2027
OH State Medical License 2012 - 2017
MI State Medical License 2009 - 2012
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Pyruvate Kinase Deficiency Natural History Study Start of enrollment: 2013 Dec 01
Completed
A Study of Ravulizumab (ALXN1210) in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria Start of enrollment: 2018 Feb 22
Completed
Phase 3
Pyruvate Kinase Deficiency Global Longitudinal Registry Start of enrollment: 2018 Apr 23
ACTIVE_NOT_RECRUITING
A Study to Evaluate Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD) Start of enrollment: 2018 Aug 09
Completed
Phase 3
A Study Evaluating the Efficacy and Safety of AG-348 in Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD) Start of enrollment: 2018 Jun 26
Completed
Phase 3
A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Regularly Transfused, Followed by a 5-Year Extension Period Start of enrollment: 2022 Jun 08
ACTIVE_NOT_RECRUITING
PHASE3
A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Not Regularly Transfused, Followed by a 5-Year Extension Period Start of enrollment: 2022 Jun 06
ACTIVE_NOT_RECRUITING
PHASE3
A Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Crovalimab for the Management of Acute Uncomplicated Vaso-Occlusive Episodes (VOE) in Participants With Sickle Cell Disease (SCD). Start of enrollment: 2022 Mar 26
COMPLETED
PHASE1
Join now to see all

Publications & Presentations

PubMed

Eculizumab is Associated With Increased Infection Rates and Infection Related Mortality in Children With Thrombotic Microangiopathy After HCT.
Michelle L Schoettler, Robert Lisac, Joel Ofori, Erin Frost, Wayne Liang
American Journal of Hematology. 2025-07-30
Characterizing pregnancy outcomes in a humanized mouse model of sickle cell disease.
Christopher Chambliss, Elizabeth Manci, Earl Fields, Jesse Bueno, Adeola Michael
British Journal of Haematology. 2025-07-20
Complement is activated in patients with acute chest syndrome caused by sickle cell disease and represents a therapeutic target.
Satheesh Chonat, Jayre A Jones, Seema R Patel, William M Briones, Michelle L Schoettler
Science Translational Medicine. 2025-07-16

Abstracts/Posters

Congenital Dyserythropoietic Anemia Type I Due to Biallelic CDAN1 mutations: Report from the Congenital Dyserythropoietic Anemia Registry (CDAR)
Satheesh Chonat, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Comorbidities and Complications in Adults with Pyruvate Kinase Deficiency
Satheesh Chonat, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Characterization of the Severe Phenotype of Pyruvate Kinase Deficiency
Satheesh Chonat, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Pyruvate Kinase (PK) Protein and Enzyme Levels in the Diagnosis and Clinical Phenotype of PK Deficiency
Satheesh Chonat, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Press Mentions

Rezurock Approved for Chronic Graft-vs-Host DiseaseAugust 4th, 2021
Ultomiris Approved for Pediatric Patients with Paroxysmal Nocturnal HemoglobinuriaJune 8th, 2021
Alexion Announces FDA Approval of ULTOMIRIS® (Ravulizumab-Cwvz) for Children and Adolescents with Paroxysmal Nocturnal Hemoglobinuria (PNH)June 7th, 2021